NEWS
SHL Medical | 2019.09

SHL joins Partnership Opportunities in Drug Delivery

SHL will proudly make its first appearance at the 2019 Partnership Opportunities in Drug Delivery (PODD) conference from October 7-8 in Boston.

The company’s debut exhibit will feature a vast array of products that provide solutions for the growing demands in self-injection treatments. Displays include Needle Isolation Technology (NIT®) – a pre-attached needle mechanism for cartridge-based auto-injectors that eliminates the need for users to manually attach the needle or directly contact with the needle upon injection preparation; the refined Molly® variation – an auto-injector family that offers devices for drug fill volumes up to 2.25mL and is designed to be mass-produced effectively and efficiently.

Owning 30 years of experience and industry knowledge, SHL continues to thrive in the self-injection treatment space, offering pharma companies a broad scope of services that include the design, development, and manufacturing of advanced drug delivery systems.

Visit SHL at Booth 24 at the Renaissance Boston Waterfront Hotel.

關於瑞健

瑞健集團為領航全球先進藥物輸送系統產業的設計、研發、及製造龍頭。其事業據點涵蓋位於瑞士、瑞典、美國及台灣的現代化設計中心以及設立於亞洲的先進製造廠房。 瑞健主要客戶為世界知名藥廠以及生技公司,提供如自動化注射器,筆型注射器以及吸入器等高科技產品。瑞健持續投資於研發製造為開發新型高科技藥物輸送系統以符合市場趨勢,其中包括使用步驟簡化、注射器精密化、拋棄式/複用式多重選擇、劑量彈性化以及藥劑濃稠度之配合等。

瑞健目前全球已有超過 4,000 名員工,主要分為以下事業群:

SHL Medical 主要為製藥和生技企業設計、研發、及製造高科技藥物傳輸系統,也提供終端組裝、醫材標籤及包裝相關服務

SHL Healthcare 從事居家及醫院護理器材之研發製造

SHL Technologies 提供醫療科技及工業設備之 OEM 製造與相關服務

如欲更深入了解瑞健集團,請至公司網站 www.shl.group.

瑞健媒體聯絡人

info@shl-group.com